Tolerability and efficacy of lacosamide monotherapy in patients with newly-diagnosed epilepsy and psychiatric comorbidities: Post hoc analysis of a prospective, randomized, double-blind trial (P5.229)

Conclusions:This post hoc analysis indicated that lacosamide monotherapy was efficacious and generally well tolerated in patients with newly-diagnosed epilepsy and psychiatric comorbidities.Study Supported by: UCB PharmaDisclosure: Dr. Schmitz received personal compensation for activities with UCB Pharma, Desitin Pharma, and Eisai as a speaker. Dr. Schmitz received research support from UCB Pharma. Dr. Newton has nothing to disclose. Dr. Dimova has received personal compensation for activities with UCB Pharma as an employee. Dr. Dimova holds stock and/or stock options in UCB Pharma. Dr. Zhang has received personal compensation for activities with UCB Pharma as an employee. Dr. Chellun has received personal compensation for activities with UCB Pharma as an employee. Dr. De Backer has received personal compensation for activities with UCB Pharma as an employee. Employee of UCB Pharma,,,,,Teresa Gasalla holds stock options of UCB Pharma,

Source: Neurology - April 17, 2017 Category: Neurology Authors: Schmitz, B., Newton, M. R., Dimova, S., Zhang, Y., Chellun, D., De Backer, M., Gasalla, T. Tags: Epilepsy and Clinical Neurophysiology: Clinical Epilepsy IV Source Type: research